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Available online xxxxDrug-induced liver injury (DILI) is among the most challenging acute or chronic liver conditions to be handled
by physicians. Despite its low incidence in the general population, DILI is a frequent cause of acute liver
failure. As such, the possibility of DILI should be considered in all patients who present with acute liver damage,
independent of any known pre-existing liver disease. DILI can be classiﬁed as intrinsic/dose-dependent
(e.g., acetaminophen toxicity) or idiosyncratic/dose-independent, with the latter form being relatively uncom-
mon. Amoxicillin–clavulanate is the antimicrobial that is most frequently associated with idiosyncratic DILI.
Large, ongoing, prospective studies in western countries have reported other drugs associated with DILI, includ-
ing nonsteroidal anti-inﬂammatory drugs, statins, and herbal and dietary supplements. An important safety
issue, DILI is one of themost frequently cited reasons for cessation of drug development during or after preclinical
studies and for withdrawal of a drug from the market. This review summarizes the epidemiology, risk factors,
commonly implicated drugs, clinical features, and diagnosis of DILI, with the aim of aiding physicians in the
management of this debated problem. Old and new biomarkers for DILI and pharmacogenetic studies are also
described.
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
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Drug-induced liver injury (DILI) encompasses adverse drug reac-
tions (ADRs) involving the liver after the administration of a xenobiotic,
such a drug or herbal and/or dietary supplement (HDS), at the usual
dose interval [1]. Theoretically, most drugs are capable of inducing
DILI, owing to the liver's pivotal role in drug metabolism.
The two main categories of DILI are intrinsic/dose-dependent
and idiosyncratic/dose-independent, with the latter form being rela-
tively uncommon. Liver injuries due to acetaminophen (N-acetyl-p-
aminophenol [APAP]) are typically associated with an excessive dose.
APAP overdose is a frequent cause of acute liver failure (ALF) requiring
liver transplantation [2,3]. Most cases of DILI are due to unpredictable
reactions and, traditionally, were believed to be dose-independent.
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drug reactions and organ daassociated with DILI, as demonstrated independently by two different
research groups [4,5]. Thus,many drugs that were previously associated
with idiosyncratic DILI are now considered to act in a dose-dependent
manner. Nevertheless, the possibility of idiosyncratic DILI should always
be considered in a patient with acute or chronic liver damage, indepen-
dent of a possible underlying liver condition (e.g., non-alcoholic
steatohepatitis or non-alcoholic fatty liver disease). As the diagnosis of
DILI remains one of exclusion, DILI is one of the most challenging
disorders to be managed by physicians and hepatologists [6].
Many drugs have been associated with DILI. Antibiotics and antimi-
crobials accounted for more than 46% of all DILI cases in the Drug-
Induced Liver Injury Network (DILIN) cohort from the United States
[7]. Among antibiotics, amoxicillin–clavulanate (AMC) was the most
frequently implicated agent, a ﬁnding conﬁrmed in prospective DILI
studies in Iceland and Spain [8,9]. Non-steroidal anti-inﬂammatory
drugs (NSAIDs), statins, and HDS can also lead to DILI. In recent years,
there has been an increase in the number of people who prefer alterna-
tive therapies, such as HDS, to commonly used drugs whose safety and
efﬁcacy have been demonstrated by controlled clinical studies. For
example, the use of HDS has increased to 3.7% in Italy, 20% in the
United Kingdom, and 40% in the United States [11,12]. Given the easy
availability of HDS via the Internet, people purchase what they deem
to be the correct preparation directly, without consulting a physician
or pharmacist. Unfortunately, patients, even those previously diagnosed
with chronic liver disease, are reluctant to disclose their use of noncon-
ventional therapies [10].
An important safety issue, DILI is one of the most frequently cited
reasons for cessation of drug development during or after preclinicalhts reserved.
mage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
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examples of drugwithdrawal in theUnited States and in Europe include
troglitazone, bromfenac [14] and others. DILI is themost common cause
of ALF in the United States [15] and Europe [16]. To increase awareness
of DILI, facilitate clinical management, and improve prognosis, the
American College of Gastroenterology developed practice guidelines
for the diagnosis and management of idiosyncratic DILI, using an
evidence-based approach [6]. Currently, however, there are no guide-
lines in Europe regarding when to suspect DILI, how to conﬁrm a
diagnosis of DILI, or how to manage DILI once it is has been recognized.
Many researchers in Europe are investigating DILI, and there is a need
for a larger European network.
The purpose of this review is to prompt physicians to consider DILI
whenever they aremanaging a patientwith an unexplained liver injury.
This review should assist physicians in accurately diagnosing DILI and
improving outcomes, given that the disorder is sometimes responsible
for ALF and occasionally requires liver transplantation. The use of
biomarkers and the impact of pharmacogenetic studies are also
discussed.
2. Epidemiology and risk factors for idiosyncratic DILI
The clinical diagnosis of DILI is one of exclusion, owing to a lack of
reliable and conﬁrmatory tests. Accordingly, it is difﬁcult to establish
the exact burden of DILI on the healthcare system. Registries of
idiosyncratic DILI cases have been established in different Western [8,
9,17,18] and Asian [19] countries. Registry data have greatly improved
knowledge regarding the etiologies, pathogenic mechanisms, and clini-
cal outcomes of DILI [20]. Patients enrolled in DILI registries are usually
middle-agedwomen (mean age: 50 years) who require hospitalization.
The clinical presentation is most often consistent with hepatocellular
liver damage, followed by a cholestatic or mixed presentation. In
population-based studies, the crude annual incidence of DILI has been
reported as 19.1 cases per 100,000 inhabitants in Iceland [8], and 13.9
cases per 100,000 inhabitants in France [18].
Some routinely used drugs are more hepatotoxic than others. AMC,
which has been associated with cholestatic liver injury, is the most
frequently prescribed antimicrobial agent worldwide, with more than
70 million prescriptions each year in the United States alone. In a
study of DILI in an Icelandic population, AMC was the most frequently
implicated agent, with an estimated DILI risk of 1 case per 2350 AMC
users. Using data from the DILIN database, Fontana [20] showed that
AMCwas responsible for almost 120 cases of DILI each year. In contrast,
isoniazid (INH), with fewer than 200,000 prescriptions per year, was
responsible for 50 DILI cases per year. Therefore, INH seems to be
more hepatotoxic than AMC. Patients treated with INH should have
their aminotransferase levels checked after 15 days of therapy and
monthly thereafter. An elevation of less than ﬁve-fold above the upper
limit of normal (ULN) is typical and will often normalize without
discontinuation of the drug. By contrast, in DILI registries such drugs
as beta-blockers or calcium channel blockers, despite their large use
among patients suffering from cardiovascular disease, are poorly
responsible of DILI, probably due to their scarce hepatotoxicity. Statins,
although rarely showed idiosyncratic liver injury, sometimes can be
associated with severe outcome [13,21].
Multifactorial mechanisms appear to underlie DILI [22]. Drug-
related risk factors include the drug's chemical features, dose,
route, and duration of administration. Host-related risk factors
include the patient's age, sex, genetics, previous episodes of DILI, and
underlying chronic liver disease. Environmental risk factors include
the patient's metabolic features (e.g., obesity), diet type, alcohol,
coffee, and tobacco consumption, multidrug therapy, immune state
(e.g., immunocompromised), and nutritional status [20,22,23] (Fig. 1).
According to the international literature, women develop DILI more
often than men, perhaps because women are the main consumers of
herbal products. Polypharmacy is a frequent cause of ADRs and longerPlease cite this article as: Licata A, Adverse drug reactions and organ da
j.ejim.2015.12.017hospital stays in the elderly [24]. Aging results in a broad range of phys-
iological changes that decrease the tolerability proﬁle of drugs. In addi-
tion, cognitive disorders may worsen compliance to with multidrug
therapy [25].
3. Clinical features and diagnosis of DILI: causality assessment
systems
Clinically, DILI represents a wide spectrum of diseases with diverse
biochemical and histologic features. A clinical picture resembling acute
hepatitis is themost common clinical presentation of acute liver disease
of all etiologies and is pathognomonic of DILI. Other clinical features of
hepatotoxicity may also be present, such as cholestatic hepatitis,
nodular regeneration, cirrhosis, non-alcoholic fatty liver disease, veno-
occlusive disease, and vanishing bile duct [20]. Liver biopsymay support
the clinical diagnosiswhen typical histopathologic ﬁndings are detected
[26]. However, histologic evaluation is infrequently performed in favor
of Fibroscan®, and DILI patterns are often deﬁned through biochemical
data alone. Due to the lack of pathognomonic features or speciﬁc
diagnostic criteria, there is no consensus regarding adequate terminolo-
gy for deﬁning the various clinical patterns of DILI.
Consensus criteria for a diagnosis of DILI [27] include a chronological
relationship between drug intake and hepatitis onset, as well as the
presence of any one of the following conditions: an alanine aminotrans-
ferase (ALT) level of more than ﬁve-fold above the ULN; an alkaline
phosphatase (ALP) level of more than two-fold above the ULN; or an
ALT level of more than three-fold above the ULN, with the simultaneous
elevation of bilirubin levels to more than two-fold above the ULN. The
liver injury pattern can be assessed by the R value, where R = (ALT/
ULN)/(ALP/ULN), with R ≥ 5 reﬂecting a hepatocellular pattern,
2 b R b 5 reﬂecting a mixed pattern, and R ≤ 2 reﬂecting a cholestatic
pattern of liver injury.
Althoughmany patientswithmild liver damage are diagnosed in the
outpatient clinic, those with severe liver injury commonly require
hospitalization and, occasionally, intensive care as a bridge to liver
transplantation. The hepatocellular pattern of liver injury exposes
patients to a risk of ALF. Hy's rule [28] predicts a mean rate of mortality
(or liver transplantation, as a surrogate marker) of 10% for jaundiced
patients with acute hepatocellular damage. This rule, originally ob-
served by Zimmerman, was recently conﬁrmed in at least two studies
[9,21]. These studies identiﬁed additional variables, such older age,
female sex, and AST levels, to be independently associated with poor
outcome. APAP, halothane, and cocaine toxicity, as well as mushroom
poisoning, typically result in acute or subacute liver failure. Toxicity by
NSAIDs, such as diclofenac and nimesulide, results in massive necrosis.
Patients with cholestatic liver damage usually present with jaundice
and itching. The canalicular pattern is characterized by an increase in
conjugated bilirubin, ALP, and γ-glutamyltranspeptidase levels, with
minimal to no elevation of aminotransferase levels. Steroids typically
produce this pattern of hepatotoxicity. The mixed pattern of liver dam-
age resembles features of hepatocanalicular damage, recalling acute
biliary obstruction. Hypersensitivity features sometimes occur and are
important clues to aid in the diagnosis. Typical examples of drugs that
cause mixed liver damage are AMC, macrolides, neuroleptics, and simi-
lar compounds [29].
Fromanosographic perspective, there is a propensity to try to distin-
guish the various patterns of liver damage and to associate speciﬁc
drugs with each pattern. However, it is not always possible to make
such associations. The clinical pattern of hepatotoxicity may vary
depending on the interaction between drug factors (e.g., dose, bioavail-
ability, and duration of treatment) and host factors (e.g., age, sex, and
drug absorption). For example, AMC frequently causes acute cholestasis
or cholestatic hepatitis in men over 65 years old, whereas a mixed
pattern is more likely in younger patients [7]. Nimesulide, an NSAID
that is commonly used for osteoarticular pain relief, can cause hepato-
cellular damage in young women, sometimes leading to ALF requiringmage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
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Fig. 1. Pathogenesis of DILI is multifactorial and depends on complex interplay made by the interaction among drug, host and environmental factors. The multi-drug therapy and the
immune compromised status are features mainly characterizing the elderly, which consequently become an “at risk condition” for ADRs.
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frequently observed [30] (Fig. 2).
DILI is largely diagnosed through a detailed clinical history,
biochemical tests, hepatobiliary imaging, and liver biopsy [6]. Some di-
agnostic algorithms are available, such as the Roussel Uclaf causality as-
sessment method (RUCAM) [31,32] and the Maria & Victorino
assessment method. RUCAM scores employ the temporal relationship
between drug intake and clinical presentation (latency), the clinical
course after drug discontinuation (dechallenge), and the response
upon rechallenge. The Maria & Victorino assessment score [33] subse-
quently published adds to the parameters the exclusion of alternative
causes of liver injury and the coexistence of extrahepatic and
immune-allergic manifestations (e.g., fever, rash, arthralgia, eosinophil-
ia). Hepatotoxicity causality assessment scores show low concordanceMixed
ALT/AP > 5
2 < AL
Hepatocellular Prevalent 
Fig. 2. Pattern of liver damage is not always the samewith a given drug. For example, AMC freq
mixed pattern is more likely in younger. Nimesulide causes hepatocellular damage in young w
damage is more frequently observed.
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The clinical utility of RUCAM results from the topics that it requires the
clinician to addressed in cases of suspected hepatotoxicity, which im-
prove the consistency of clinical judgment [34].
4. Drugs frequently involved in DILI
Almost any class of drug can be involved in idiosyncratic DILI. None-
theless, in the United States, antimicrobials and antidepressant/antipsy-
chotics are the most commonly implicated drug classes, followed by
NSAIDs, antiplatelet agents, statins, and HDS [6]. Since 2000, we have
followed a prospective cohort of consecutive DILI patients at our tertiary
referral center. This cohort primarily consists of women (54%), with a
mean age of 54 years. We reported that almost 25% of patients in theALT/AP < 2
T/AP > 5 
Cholestasis Prevalent
uently causes acute cholestasis or cholestatic hepatitis inmen over 65 years old, whereas a
omen, sometimes leading to ALF requiring liver transplantation. In men cholestatic liver
mage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
Table 1
Clinical features of 157 patients with drug induced liver injury seen at our tertiary referral
center: the impact of NSAIDs.
NSAIDs
(n= 61)
Other drugs
(n= 96)
p
Age (years) 48.1 ± 18.4 55.1 ± 17.6 0.02
Duration of drug intake (days) 11.2 ± 24.6 60.1 ± 114.2 b0.001
Latency (weeks) 29.2 ± 16.2 57.1 ± 90.6 0.02
Hepatic encephalopathy at diagnosis 5 (8.2%) 1 (1.1%) 0.02
Pattern of DILI
Hepatocellular 42 (68.8%) 41 (42.7%) 0.006
Cholestatic 11 (18.0%) 32 (33.3%)
Mixed 8 (13.2%) 23 (24.0%)
ALT (IU/L) 744.2 ± 755.7 427.6 ± 512.2 0.02
Eosinophils (%) 1.9 ± 1.9 3.1 ± 4.2 0.02
Stiffness (KPa) 9.4 ± 6.6 11.3 ± 8.4 0.6
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tocellular pattern was observed in 53% of cases, followed by cholestatic
(27%) and mixed patterns (20%). The most frequently involved drugs
were NSAIDs (~40%), followed by antibiotics, immunosuppressants,
antiplatelet agents, antidiabetic drugs, and statins. In the 24% of DILI
cases, two or more drugs were involved [35] (see Table 1 and Fig. 3).
Nimesulide was the most commonly implicated NSAID, responsible
for hepatocellular DILI in women and the cholestatic/mixed type in
men [30,36]. Among antibiotics, we reported the impact of AMC-
induced [37] and ﬂuoroquinolone-induced [38] liver injury.
Fromour prospectively followedDILI cohort,we recently identiﬁed a
small group of 12 patients who had drug-induced autoimmune hepati-
tis (DIAIH). Liver biopsy specimens from these patients featured severe
portal inﬂammation and lymphoplasmacytic inﬁltrates. Despite their
briefer drug exposure period compared to DILI patients, DIAIH patients
displayed higher aminotransferase and γ-globulin values [39]. These
data support the importance of correctly distinguishing between
DIAIH andDILI, and emphasize the key role of liver biopsy in the diagno-
sis, prognosis, and follow-up of affected patients [26,39].
5. APAP-induced liver injury
APAP-induced hepatotoxicity represents one of the best examples of
predictive DILI, causing rapid liver injury in the centrilobular region
[14]. Liver damage can be intentional (e.g., attempted suicide) or
accidental (e.g., inadvertent drug intake in excess of the intended dose
over several days). APAP is widely used as an analgesic and is available
inmany nonprescription and prescription products, including in combi-
nation with opioids [40]. For this reason, APAP overdose is the most
common cause of ALF and death due to analgesics [41,42] in Anglo-
Saxon countries, with over 500 deaths per year in the United States.Fig. 3. Drugs commonly involved as causes of drug induced liver injury in a cohort of 157
patients prospectively followed at our tertiary referral center.
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room annually, at an annual cost of more than $86 million [43,44].
Patients presenting to the emergency room with a report of APAP
ingestion are assessed for treatment with N-acetyl cysteine (NAC),
which is effective in most cases if given early. Onset of liver damage
can only be prevented within about 8 to 10 h of APAP ingestion. Thus,
the time to NAC administration is themost relevant factor in preventing
injury by APAP. A careful medical history, clarifying the quantity
ingested, the blood concentration of APAP, and the extreme values of
ALT (up to 3000 UI/L), help clinicians to differentiate between APAP
poisoning and other causes of ALF (e.g., viral hepatitis, ischemia) [14].
There are limitations to the use of ALT as a biomarker for assessing
patient status after APAP ingestion. Although serum ALT levels are
elevated as a rule, they may take more than 72 h to peak. For the best
outcome, NAC should be administered as soon as possible after APAP in-
gestion, while promptly diagnosing the patient.
Recently, Ward et al. [45] identiﬁed a set of 11 small, noncoding
microRNAs (miRNAs) whose proﬁles and dynamics can discriminate
APAP hepatotoxicity from ischemic acute hepatitis. Wang et al. [46]
demonstrated that, in mice overdosed with APAP, blood levels of
miRNA 122 and 192 were increased. The same miRNAs were subse-
quently detected in human plasma as well [47].
Although dose is a predictor of outcome in patients with APAP
toxicity, the actual toxic dose remains unclear [48]. Most international
guidelines recommend 200 mg/kg or 10 g as the toxic dose. Currently,
the gold standard for starting NAC therapy is a single serum APAP
concentration above the nomogram between 4 and 24 h from ingestion
[49]. A recently published Australian study on patients presenting with
APAP overdose at a tertiary referral center showed that themedian dose
of APAP ingested was 10 g among 1303 patients (1140 women, median
age of 27 years). In 22% of patients, the APAP concentration was above
the nomogram line. For many years, guidelines for patients presenting
with APAP overdose within 8 h of ingestion recommended a “wait and
see” approach while testing the serum APAP concentration. However,
current guidelines suggest thatmore than 90% of patientswith a report-
ed dose greater than 50 g will require treatment with NAC. Therefore,
NAC should be started immediately in these patients [48].
Finally, ALF due to APAP toxicity has a better overall survival rate
(70%) compared to ALF due to DILI by other drugs (58%), despite the
initial severity of APAP overdose. This phenomenon could be due to
the rapid evolution of the clinical course,which also induces rapid hepa-
tocyte regeneration and, thus, resolution of liver damage [6,15].
6. Pathogenic mechanisms of DILI
After biotransformation by the cytochrome P450 system, a drug can
become an active metabolite that is less toxic, more hydrophilic, and
ready to be eliminated. Subsequently, UDP-glucuronosyltransferase,
sulfotransferase, and glutathione-S-transferase hydrolyze the metabo-
lite. Transport of the metabolite out of hepatocytes is mediated by the
ATP binding cassette (ABC) transporter superfamily [50]. In general,
drugs can either directly affect hepatocytes/cholangiocytes or elicit an
innate or adaptive immune reaction [14]. In most cases bioactivation
of a drug leads to a reactive metabolite that causes mitochondrial
dysfunction, cytoskeletal breakdown, and cell membrane disruption.
In other cases, however, bioactivation can inﬂuence the transport of
proteins (e.g., MDR-3), resulting in an interruption of bile ﬂow and
bilirubin excretion, causing cholestasis [51–53].
As an alternative to direct action, hepatocyte stress results in the
activation of the innate immune system through natural killer cells of
the liver, which kill cells through the Fas/Fas ligand pathway. Kupffer
cells contribute to the progression of liver damage by producing
proinﬂammatory mediators, cytokines, and chemokines, mediating
cytotoxicity by degrading the extracellular matrix, and promoting cell
adhesion and leukocyte inﬁltration. This mechanism, commonly
known as apoptosis, is considered a non- or low-inﬂammatory process,mage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
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system is also involved in the pathogenesis of liver damage. If an active
metabolite is able to act as a hapten and covalently bind host proteins,
then the immune system will perceive the metabolite as foreign,
triggering an inappropriate T-cell response [55]. This necrotic process
is the type of liver damage observed after APAP hepatotoxicity. A third
form of cell death, necroptosis, incorporates features of both necrosis
and apoptosis [56]. Necroptosis is better characterized in the setting of
TNF-induced cell death (e.g., patients with acute hepatocellular DILI),
although it may also occur in acutely developing conditions, such as
ischemia-reperfusion injury.
7. Biomarkers of DILI
Currently, there are no clearly identiﬁed biomarkers of DILI that are
useful for monitoring patients on drug therapy for early detection of
hepatotoxicity or for making an appropriate diagnosis. Traditionally,
ALT, ALP, and total bilirubin levels have been used clinically to identify
the various types of DILI. However, patterns of liver injury may be
categorized by the pathological conditions and underlying events,
such apoptosis, necrosis, and necroptosis, inﬂammation, oxidative
stress, and immune system activation, all of which contribute to liver
injury.
Studies have recently proposed candidate biomarkers for liver injury
and mitochondrial dysfunction, all of which are related to the potential
mechanisms involved in DILI pathogenesis. Not all of these biomarkers
are used clinically [20,54] (Table 2). For example, cytokines T helper
(Th) 1-type (IL-12, IFN-γ, IL-2, IL15) and Th2-type (IL-4, IL-5, IL-13)
are usually activated in response to acute immune stimuli. If the inﬂam-
matory state does not resolve, then chronic inﬂammation could evolve
into an adaptive immune response, with activation of Th17/Th9 cell
types, resulting in a poor prognosis [57]. Recently, miRNA 122 andTable 2
Established and emerging biomarkers associated with acute and chronic liver damage
(modiﬁed from Fontana [20]).
Marker Pattern of injury Disease
Liver injury biomarkers
ALT, AST, AP bilirubin Acute and chronic
liver injury
All liver disease, hepatitis,
viral and autoimmune,
NASH, NAFLD
Sorbitol dehydrogenase Acute liver injury Acute liver disease
Glutatione S-transferase Liver and kidney
injury
(mitochondrial
damage)
Chronic liver disease
Glutamate dehydrogenase Chronic liver injury Chronic liver disease
Serum cytokines pattern
Th 1 (IL-2, IFNγ,
IL-12,IL-15)
Acute liver injury Acute liver disease
Th2 (IL-4, IL-5, IL-13) Acute liver injury Acute liver disease
Th9/Th17 Chronic liver injury Chronic liver disease
miRNAs
miR-122 Acute and chronic
liver injury
APAP overdosing
miR-192 Acute and chronic
liver injury
APAP overdosing
Cell death biomarkers
HMGB-1 (High mobility
group box1)
Acute liver injury
(Necrosis)
APAP overdosing
Cytokeratin (CK) 18
fragments
Acute and chronic
liver injury
ALD, NASH, viral hepatitis
M-30 Acute liver injury
(Apoptosis)
Acute liver failure
M-65 Acute liver injury
(total hepatocytes
death)
Acute liver failure
Proteomics biomarkers
Fructose biphosphonate
aldolase B, apolipoprotein E,
apolipoprotein A
Acute and chronic
liver injury
Acute and chronic liver
disease
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thesemiRNAs parallel ALT levels during hepatotoxicity, increasing early
in the course of liver damage. These miRNAs may have prognostic sig-
niﬁcance in patients with ALF after APAP overdose [46]. Another
group of biomarkers includes molecules related to the apoptotic and/
or necrotic process [20,58,59]. Finally, an emerging area being studied
for biomarkers in patients with DILI is proteomics, with studies examin-
ing both serum and urine [60].
8. Pharmacogenetic impact of DILI
Susceptibility to drugs depends on the presence of genetic variations
among gene classes, such as those involved in drug disposition/trans-
port, cellular stress, and inﬂammatory and immune response genes,
including the human leukocytes antigen (HLA) system [61,62]. Different
drugs may share speciﬁc genetic susceptibility variants [63]. Further-
more, as some patients experience multiple DILI episodes caused by
different drugs, there may exist a subgroup of individuals that is
predisposed to DILI [63]. Because genetic susceptibility is an important
feature of severe ADRs [64,65], there is a growing interest in developing
genetic tests to identify people at risk for adverse events before
prescription.
The success of genome-wide association studies (GWAS) in identify-
ing susceptibility genes for polygenic diseases [66] has led to an interest
to applyingGWAS to serious ADRs [67]. In general, GWAS are particular-
ly suitable for detecting small effects. However, the small number of
analyzed cases limits the ability of GWAS to detect signiﬁcant effects
[68]. To overcome this limitation, large networks have been established
in the United States and Europe, facilitating recruitment of patientswith
DILI [17,69].
8.1 HLA, immune response, and DILI susceptibility
A traditional example of HLA association with idiosyncratic DILI is
represented by halothane, a general anesthetic that was an important
cause of acute hepatitis in the operation room. Previous studies have
described associations between HLA genes and liver damage caused
by halothane [70], diclofenac, and/or chlorpromazine [71]. More
recently, a study of theHLA genotyping has been carried out on patients
with AMC-related DILI. Although this form of DILI usually does not
manifest typical immune-related features, an association with the
HLADRB1*15:01 allelewas reported [72]. Subsequent studies using can-
didate genes and GWAS methods identiﬁed multiple HLA class I and II
associations [73]. In our study of 12 patients with DIAIH, we identiﬁed
a genetic susceptibility to nimesulide and other xenobiotics [39],
supporting the hypothesis of an autoimmune pathogenesis in these
patients (Table 3). Recently, the concept that HLA alleles are risk factors
for ﬂucloxacillin-, ximelagatran-, and lumiracoxib-induced liver injury
[74–76] has become more widely accepted. Hepatotoxicity arising
from these agents appears to involve the immune system, with DILI
resulting from inappropriate T-cell responses, possibly due to skewing
of the T-cell repertoire [77–79].
A few studies have investigated the association between cytokine
genetic polymorphisms and the risk of DILI. In 2004, Aithal [80] reported
that the frequencies of variant alleles for interleukin (IL)-10 and IL-4
were signiﬁcantly higher in patientswith diclofenac-induced liver dam-
age compared to subjects who received diclofenac but did not develop
hepatitis. Liang et al. [81] showed that IL-10–592 AA and IL-10–819 TT
genotypes signiﬁcantly increased the incidence of DILI in breast cancer
patients. However, another study failed to conﬁrm these results [82].
Nonetheless, it seems that cytokine genetic polymorphisms are biolog-
ically likely risk factors thatmay contribute to the risk of DILI, given that
polymorphisms for IL-6, STAT3, and HSPA1L confer a higher risk of
developing hepatotoxicity from antitubercular drugs [83].
GWAS of DILI have failed to identify novel single-nucleotide
polymorphisms (SNPs) in HLA genes showing strong effects [68].mage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
Table 3
HLA and non-HLA genes associated with drug induced liver injury (DILI) (modiﬁed from Daly [79]).
HLA associated genes
Pattern of reaction Drugs HLA loci
Liver Hepatocellular/Cholestatic type Amoxicillin–clavulanate DRB1*1501-DQB1*0602 A*0201
Cholestatic type Flucloxacillin B*5701
Hepatocellular type Ximelagatran DRB1*0701-DQA1*0201
Cholestatic type Ticlopidine A*3303
Cholestatic type Lumiracoxib DRB1*1501-DQB1*0602
Hepatocellular/Mixed type Nimesulide DRB1*0708-DQB1*0204 DRB1*0713-DQB1*0206
Hepatocellular type Ketoprofen DRB1*0413-DQB1*0306
Hepatocellular type Green Tea DRB1*0103-DQB1*0205
Non-HLA associated genes
Drug metabolism and transporters (ATP binding cassette) Liver injury Phase II
Isoniazid NAT2
Diclofenac UGT2B7
UGT1A
Myopathy/Liver injury Simvastatin Transporters SLCO1B1
Liver injury Diclofenac ABCB11 ABCC2
Hepatocellular 1549
Cholestatic 1774
Immune and inﬂammatory system Liver injury Diclofenac IL-4 C590A
IL-10 C627A
Liver injury Anti tubercular drugs IL-6
Liver injury Amoxicillin–clavulanate STAT-4
Flucloxacillin STAT3
Anti tubercular drugs ST6GAL1
6 A. Licata / European Journal of Internal Medicine xxx (2016) xxx–xxxHowever, further analysis of data obtained from patients with DILI
induced by ﬂucloxacillin [84] showed that patients with HLA-B*57:01
have a signiﬁcant association with a SNP close to ST6GAL1, a gene
contributing to B-cell activation responses [85]. Moreover, Lucena
et al. [73] showed a signiﬁcant association for a SNP in the STAT4 gene
in their examination of DILI cases. STAT4 triggers activation of IL-12
and IL-23 signaling during T-cell responses [86]. This SNP has been
previously associated with other autoimmune diseases, representing
another likely risk factor for DILI.8.2 Drug disposition and transporter gene susceptibility
A polymorphism of the N-acetyltransferase-2 (NAT-2) gene
represents a well-known example of a genetic predisposition to
DILI. NAT-2 is the enzyme responsible for the metabolism of INH.
Several studies have reported that patients who are slow acetylators
(i.e., homozygous for both NAT-2 alleles) completely lack enzyme
activity and, therefore, are at risk for developing liver injury [87].
However, being a slow acetylator is not sufﬁcient [88] to cause the
toxicity, because many of the patients analyzed showed only mild in-
creases of aminotransferase levels. These elevations resolved easily
after transient drug withdrawal and usually did not recur when INH
therapy resumed.
Transporter genes in theABC superfamily are biologically reasonable
candidates for genetic susceptibility to DILI [89]. Some inherited forms
of cholestasis result from speciﬁc mutations in the ABCB4 (MDR3) and
ABCB11 (BSEP) genes [90]. In addition, a great deal of evidence
correlates cholestatic liver injury from diverse drugs to the presence of
a polymorphism in the ABCB11 gene, which is also associated with
intrahepatic cholestasis of pregnancy [91]. The ABCC2 (MRP2) gene
has an important role in the biliary excretion of diverse glucuronide
conjugates. Daly et al. [92] reported that a polymorphism in ABCC2
(C24T) was common among patients with diclofenac-induced liver
injury. This result was consistent with the increased levels of active
metabolites of diclofenac, largely toxic, in the absence of the polymor-
phism C24T, which results in low production of the MRP2 protein and,
thus, the accumulation of the glucuronide. However, two polymor-
phisms of ABCC2have been identiﬁed, one−1549 in linkage disequilib-
rium with C-24T, already known risk factor for hepatocellular liverPlease cite this article as: Licata A, Adverse drug reactions and organ da
j.ejim.2015.12.017injury, and a second at−1774 of ABCC2, which indeed is a risk factor
for cholestatic and mixed liver damage [93].
There are reports of associations between the UGT genotype
and DILI. UGT2B7*2 is associated with an increased susceptibility to
diclofenac-related DILI. The pathogenic mechanism could be due to
high levels of the metabolite, diclofenac acylglucuronide [92].
Statins are the most commonly prescribed agents for lowering low-
density lipoprotein cholesterol levels, because of their excellent
tolerability and safety. However, in some individuals, statins
can cause liver and muscle damage, as evidenced by increased levels
of aminotransferase and creatine-phosphokinase. These elevations
are promptly reversed on drug discontinuation. Although typically
asymptomatic, the increased levels can also become severe, leading
to rhabdomyolysis [94]. A GWAS involving simvastatin-induced
myopathy cases identiﬁed an SNP in SLCO1B1. This gene encodes a
transporter, organic anion transporting polypeptide-1 (OATP1B1),
which is responsible for the transport of statins and other drugs
from the bloodstream into the cell [95]. The association between
SLCO1B1 and statin-inducedmyopathy was subsequently conﬁrmed
[96]. Because the overall contribution of SLCO1B1 to hepatic trans-
port is likely to vary across statins, the contribution of the
SLCO1B1*5 polymorphism may vary among different statins [97].
Learning points
• An important safety issue, DILI is one of the most frequently cited
reasons for cessation of drug development during or after preclinical
studies and for withdrawal of a drug from the market. It is the most
common cause of ALF in western countries.
• Almost all drug classes can be involved in idiosyncratic DILI. Antimi-
crobials, antidepressant/antipsychotics and NSAIDs are the most
common implicated drugs classes followed by, anti-platelets agents,
statins and HDS; recently, body building products and slimming aids
have shown a relevant increase of consumption.
• Hepatotoxicity by acetaminophen (APAP) represent the best example
of predictive DILI, causing rapidly hepatocellular liver injury. Patients
claimed APAP ingestion have to be assess for treatment with N-acetyl
cysteine (NAC). Timing of NAC administration (8–10 H) is the most
relevant factor in preventing injury by APAP.
• There are no clearly identiﬁed biomarkers of DILI that are useful formage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
7A. Licata / European Journal of Internal Medicine xxx (2016) xxx–xxxmonitoring patients on drug therapy for early detection of hepatotox-
icity or formaking an appropriate diagnosis. AST, ALT, AP and bilirubin
are able to identify hepatocellular, cholestatic and/ormixed pattern of
liver damage.
• Susceptibility to drugs mainly depends on the presence of genetic
variation among gene classes, such as drug disposition/transporters
genes, inﬂammatory and immune response genes, including HLA
system. There is growing interest in developing genetic tests to iden-
tify people at risk for adverse events before prescription.
Concluding remarks
This review was aimed at highlighting knowledge regarding the
epidemiology, risk factors, clinical features, and diagnostic criteria of
idiosyncratic and dose-related DILI. Diagnosis of DILI remains a debated
issue, despitemany efforts to identify proper diagnostic criteria anduseful
biochemicalmarkers to assist physicians and predict outcomes. In this ar-
ticle, I have reported the most commonly implicated medications, the in-
creasing use of HDS, the difﬁculties of diagnosis with currently available
causality assessment methods, and the new biomarkers being developed
for DILI. I have reviewed the issue of APAP overdose-related ALF and its
management. I have also provided an update of the literature and discus-
sion of the genetic susceptibility risks of patients with DILI. Nevertheless,
substantial research is still needed before useful predictors of risk can be
established to deﬁne patients susceptible to developing DILI.
Conﬂict of interest
None.
Acknowledgment
I am really thankful to Antonio Craxì for his valuable advice and
support in reviewing the manuscript.
References
[1] Einar S. Bjornssn. Drug-induced liver injury: an overview over the most critical
compounds. Arch Toxicol 2015;89:327–34.
[2] Lee W. Acetaminophen-related acute liver failure in the United States. Hepatol Res;
38 (S1):S3-8.
[3] Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute
liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;
137:947–95.
[4] Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al.
Determinants of the clinical expression of amoxicillin–clavulanate hepatotoxicity:
a prospective series from Spain. Hepatology 2006;44(4):850–6.
[5] Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship
between daily dose of oral medications and idiosyncratic drug-induced liver injury:
search for signals. Hepatology 2008;47(6):2003–9.
[6] Chalasani N, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al.
Practice Parameters Committee of the American College of Gastroenterology. ACG
Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced
liver injury. Am J Gastroenterol 2014;109(7):950–66.
[7] Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes
from a prospective study of drug induced liver injury in the United States. Gastroen-
terology 2008;135:1924–34.
[8] Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence,
presentation, and outcomes in patients with drug-induced liver injury in the general
population of Iceland. Gastroenterology 2013;144(7):1419–25 1425.
[9] Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E et al. Drug-
induced liver injury: an analysis of 461 incidences submitted to the Spanish registry
over a 10-year period. Gastroenterology 2005;129(2):512–21.
[10] Vitalone A, Menniti-Ippolito F, Moro P, Firenzuoli F, Raschetti R, Mazzanti G. Suspected
adverse reactions associatedwith herbal products used for weight loss: a case series re-
ported to the Italian National Institute of Health. Eur J Clin Pharmacol 2011;67:215–24.
[11] Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver
injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury
Network. Hepatology 2014;60(4):1399–408.
[12] A Licata A, Macaluso FS, Craxì A. Herbal hepatotoxicity: a hidden epidemic. Intern
Emerg Med 2013;8(1):13–22.
[13] Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731–9.
[14] Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349(5):474–85 31.Please cite this article as: Licata A, Adverse drug reactions and organ da
j.ejim.2015.12.017[15] Reuben A, Koch DG, Lee WM. Acute Liver Failure Study Group. Drug-induced acute
liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;
52(6):2065–76.
[16] Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, et al. Acute liver
failure in Sweden: etiology and outcome. J Intern Med 2007;262(3):393–401.
[17] Hoofnagle JH. Drug-Induced Liver Injury Network (DILIN). Hepatology 2004;40:773.
[18] Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-
induced hepatic injuries: a French population-based study. Hepatology 2002;36(2):
451–5.
[19] Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in
Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009;39(5):
427–31.
[20] Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical
perspective. Gastroenterology Apr. 2014;146(4):914–28.
[21] Björnsson E, Olsson R. Outcome and prognosticmarkers in severe drug-induced liver
disease. Hepatology 2005;42(2):481–9
[22] Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury:
interactions between drug properties and host factors. J. Hepatol. 2015 ;
63(2):503–14
[23] Ghabril M, Chalasani N, Björnsson E. Drug-induced liver injury: a clinical update.
Curr Opin Gastroenterol 2010;26(3):222–6.
[24] Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, et al. Polypharmacy,
length of hospital stay, and in–hospital mortality among elderly patients in internal
medicine wards. The Reposi study. Eur J Clin Pharmacol 2011;5:507–19.
[25] Mannucci PM. NobiliA: Reposi investigators. Intern Emerg Med 2014;9:723–34.
[26] Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimi-
nation of idiopathic autoimmune hepatitis versus drug-induced liver injury.
Hepatology 2011;54:931–9.
[27] Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case
deﬁnition and phenotype standardization in drug-induced liver injury. Clin
Pharmacol Ther 2011;89:806–15.
[28] Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on
the liver. Philadelphia: Lippincott Williams & Wilkins2nd ed. ; 1999.
[29] Andrade R, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC,
Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a
challenge for gastroenterologists. World J Gastroenterol 2007;13(3):329–40 21.
[30] Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Büscher H, Laporta T, et al.
Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol Jul. 1998;
29(1):135–41.
[31] Danan G, Benichou C. Causality assessment of adverse reactions to drugs— I. A novel
method based on the conclusions of international consensus meetings: application
to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323–30.
[32] Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to
drugs — II. An original model for validation of drug causality assessment methods:
case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331–6.
[33] Maria VA, Victorino RM. Development and validation of a clinical scale for the
diagnosis of drug-induced hepatitis. Hepatology 1997;26:664–9.
[34] Lucena MI. Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F.
Comparison of two clinical scales for causality assessment in hepatotoxicity.
Hepatology 2001;33:123–30.
[35] Licata A, Butera G, Maida M, Calvaruso V, Cappello M, Craxì A, et al. Drug-induced
liver inujry: the impact of non steroidal anti-inﬂammatory drugs (NSAIDS). J
Hepatol 2013;58(S6):S227 # 539.
[36] Licata A, Calvaruso V, Cappello M, Craxì A, Almasio PL. Clinical course and outcomes
of drug-induced liver injury: nimesulide as the ﬁrst implicatedmedication. Dig Liver
Dis 2010;42(2):143–8.
[37] Licata A, Randazzo C, Butera G, Calvaruso V, Calì A, Cappello M, et al. Pattern of drug
induced liver injury: the impact of amoxicillin–clavulanate on severity of clinical
course. J Hepatol 2011;54(S1):S203 # 497.
[38] Licata A, Randazzo C, Morreale I, Butera G, D'Alessandro N, Craxì A. Fluoroquinolone-
induced liver injury: three new cases and a review of the literature. Eur J Clin
Pharmacol May 2012;68(5):525–32.
[39] Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, et al. Clinical features
and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective
cohort study. Dig Liver Dis Dec. 2014;46(12):1116–20.
[40] Doyon S, Klein-Schwartz W. Hepatotoxicity despite early administration of intrave-
nous N-acetylcysteine for acute acetaminophen overdose. Acad Emerg Med 2009
Jan;16(1):34–9.
[41] Craig DG, Lee A, Hayes PC, Simpson KJ. Review article: the current management of
acute liver failure. Aliment Pharmacol Ther 2010;31(3):345–58.
[42] Bronstein AC, Spyker DA, Cantilena Jr LR, Green JL, Rumack BH, Gifﬁn SL. Annual Report
of the American Association of Poison Control Centers' National Poison Data System
(NPDS): 26th annual report. Clin Toxicol (Phila) 2009;47(10):911–1084.
[43] Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-
induced acute liver failure: results of a United States multicenter, prospective study.
Hepatology Dec. 2005;42(6):1364–72.
[44] Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for over-
doses of acetaminophen containing products. Am J Prev Med 2011;40(6):
585–92.
[45] Ward J, Kanchagar C, Veksler-Lublinsky I, Lee RC, McGill MR, Jaeschke H, et al. Circu-
lating microRNA proﬁles in human patients with acetaminophen hepatotoxicity or
ischemic hepatitis. Proc Natl Acad Sci U S A 2014;111(33):12169–74 19.
[46] Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating
microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci
U S A Mar. 14 2009;106(11):4402–7.mage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
8 A. Licata / European Journal of Internal Medicine xxx (2016) xxx–xxx[47] Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating
microRNAs as potential markers of human drug-induced liver injury. Hepatology
2011;54(5):1767–76.
[48] Duffull SB, Isbister GK. Predicting the requirement for N-acetylcysteine in paraceta-
mol poisoning from reported dose. Clin Toxicol 2013;51(8):772–6.
[49] Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA. Panel of Australian and New
Zealand clinical toxicologists. Guidelines for the management of paracetamol poi-
soning in Australia and New Zealand — explanation and elaboration. A consensus
statement from clinical toxicologists consulting to the Australasian poisons informa-
tion centres. Med J Aust 2008;188(5):296–301 3.
[50] Moitra K, Dean M. Evolution of ABC transporters by gene duplication and their role
in human disease. Biol Chem Jan. 2011;392(1-2):29–37.
[51] Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug
terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-
dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21(3):403–9.
[52] Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-
endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are di-
rected against a human liver cytochrome P-450 that hydroxylates the drug. Proc
Natl Acad Sci U S A 1987;84(2):551–5.
[53] Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J
Med 1998;22(339):1217–27.
[54] Luedde T, Kaplowitz N. Schwabe RFCell death and cell death responses in liver
disease: mechanisms and clinical relevance. Gastroenterology 2014;147(4):765–83.
[55] Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of
cell demise: signalling cascades, important mediators and concomitant immune
response. Biochim. Biophys. Acta 2006;1757(9-10):1371–87
[56] Linkermann A, Green DR. Necroptosis. N Engl J Med Jan. 30 2014;370(5):455–65.
[57] Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N. Proﬁles of
serum cytokines in acute drug-induced liver injury and their prognostic signiﬁcance.
PLoS One Dec. 27 2013;8(12):e81974.
[58] Rutherford AE, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, et al. Serum
apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol
Dec. 2007;5(12):1477–83.
[59] Chung RT, Stravitz RT, Fontana RJ, Schiodt FV, Mehal WZ, Reddy KR, et al. Pathogen-
esis of liver injury in acute liver failure. Gastroenterology Sep. 2012;143(3):e1–7.
[60] Bell LN, Vuppalanchi R,Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, et al. Serum
proteomic proﬁling in patients with drug-induced liver injury. Aliment Pharmacol
Ther Mar. 2012;35(5):600–12.
[61] Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights
from genetic studies. Pharmacogenomics 2009;10:1467–87.
[62] Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics
2010;11:607–11.
[63] Lucena MI, Kaplowitz N, Hallal H, Castiella A, Garcia-Bengoechea M, Otazua P, et al.
Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish
Registry. The dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011.
[64] Wilke R, Lin DW, Roden D,Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic
risk factors for serious adverse drug reactions: current progress and challenges. Nat
Rev Drug Discov 2007;6(11):904–16.
[65] Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications
and perspectives. Pharmacogenomics 2009;10:961–9.
[66] Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000
cases of seven common diseases and 3000 shared controls. Nature 2007;447:
661–78.
[67] Daly A. Using genome-wide association studies to identify genes important in seri-
ous adverse drug reactions. Annu Rev Pharmacol Toxicol 2012;52:21–35.
[68] Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, et al. Limited contribu-
tion of common genetic variants to risk for liver injury due to a variety of drugs.
Pharmacogenet Genomics 2012 Nov;22(11):784–95.
[69] Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case–
control DNA collection for studying the genetic basis of adverse drug reactions.
Pharmacogenomics 2006;7:633–8.
[70] Otsuka S, YamamotoM, Kasuya S, Ohtomo H, Yamamoto Y, et al. HLA antigens in pa-
tients with unexplained hepatitis followinghalothaneanesthesia. Acta Anaesthesiol
Scand 1985;29:497–501.
[71] Berson A, Freneaux E, Larrey D, Lepage V, Douay C, Mallet C, et al. Possible role of
HLA in hepatotoxicity — an exploratory study in 71 patients with drug-induced
idiosyncratic hepatitis. J. Hepatol.1994, 20:336–342.
[72] O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RM.MillsPR: co-
amoxiclav jaundice: clinical and histological features and HLA classII association. Gut
2000;47:717–20.Please cite this article as: Licata A, Adverse drug reactions and organ da
j.ejim.2015.12.017[73] Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility
to amoxicillin–clavulanate-induced liver injury is inﬂuenced by multiple HLA class I
and II alleles. Gastroenterology Jul. 2011;141(1):338–47.
[74] Monshi M, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. HLA B*57:01
restricted activation of drug-speciﬁc T-cells provides the immunological basis for
ﬂucloxacillin-induced liver injury. Hepatology 2013;57(2):727–39.
[75] Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al.
Genome-wide pharmacogenetic investigation of a hepatic adverse event without
clinical signs of immunopathology suggests an underlying immune pathogenesis.
Pharmacogenomics J 2008;8:186–95.
[76] Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide
study identiﬁes HLA alleles associated with lumiracoxib-related liver injury. Nat
Genet 2010;42:711–4.
[77] Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-
reactivity triggered by drug-modiﬁed HLA peptide repertoire. Nature 2012;486:
554–8.
[78] Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug
hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.
Proc Natl Acad Sci U S A 2012;109:9959–64.
[79] Daly A. Pharmacogenomics of adverse events. Gend Med 2013;5(5):2–12.
[80] Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, et al. Hepatic ad-
ducts, circulating antibodies, and cytokine polymorphisms in patients with
diclofenac hepatotoxicity. Hepatology 2004;39:1430–40.
[81] Liang X, Zhang J, Zhu Y, Lu Y, Zhou X, Wang Z, et al. Speciﬁc genetic polymorphisms
of IL10–592 AA and IL10–819 TT genotypes lead to the key role for inducing
docetaxel-induced liver injury in breast cancer patients. Clin Transl Oncol 2013;15:
33.
[82] Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S, Fernandez MA,
et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver in-
jury (DILI) and its outcome. J Hepatol Jul. 2008;49(1):107–14.
[83] Wang J, Chen R, Tang S, Lv X, Wu S, Zhang Y, et al. Analysis of IL-6, STAT3 and
HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a
nested case–control study. PLoS One 2015;10(3):e0118862.
[84] Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701
genotype is a major determinant of drug-induced liver injury due to ﬂucloxacillin.
Nat Genet Jul. 2009;41(7):816–9.
[85] Nasirikerani M, Segal BH, Ostberg JR, Urbasic A, Lau J, et al. Altered granulopoietic
proﬁle and exaggerated acute neutrophilic inﬂammation in mice with targeted
deﬁciency in the sialyltransferase ST6gGal1. Blood 2006;108:3397–405.
[86] Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms,
and implications for autoimmunity. Curr Allergy Asthma Rep 2008;8(5):398–403.
[87] Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of
isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011;89:911–4.
[88] Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug
Metab Rev 2012;44(1):116–26.
[89] Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion
transporter regulation during cholestasis, inﬂammation and liver regeneration.
Biochim Biophys Acta 2007;1773:283–308.
[90] Noe J, Kullak-Ublick GA, Jochum W, Stieger B, Kerb R, Haberl M, et al. Impaired
expression and function of the bile saltexport pump due to three novel ABCB11mu-
tations in intrahepaticcholestasis. J Hepatol 2005;43:536–43.
[91] Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, et al. Mutations and polymor-
phisms in the bile salt export pump and the multidrug resistance protein 3 associat-
ed with drug induced liver injury. Pharmacogenet Genomics 2007;17:47–60.
[92] Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibil-
ity to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and
ABCC2 genotypes. Gastroenterology 2007;132:272–81.
[93] Choi JH, Ahn BM, Yi J, Lee JH, Nam SW, Chon CY, et al. MRP2 haplotypes confer dif-
ferential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007;17:
403–15.
[94] Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry
2009;80:832–8.
[95] Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants
and statin-induced myopathy — a genome wide study. N Engl J Med 2008;359:
789–99.
[96] Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5
genetic variant is associated with statin-induced side effects. J Am Coll Cardiol
2009;54:1609–16.
[97] Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther
2010;87:130–3.mage: The liver, Eur J Intern Med (2016), http://dx.doi.org/10.1016/
